Neuroglee Therapeutics is a digital therapeutic platform created to treat patients in the early stages of the disease.
Neuroglee Therapeutics has raised $10.0M in total funding. The most recent round was Series A. The last funding was announced in September 2021.
Neuroglee Therapeutics's investors include EDBI, Openspace Capital, Eisai, Kuldeep Rajput, Raman Singh.
Neuroglee Therapeutics is headquartered in Singapore, Singapore.
Neuroglee Therapeutics is a digital therapeutic platform created to treat patients in the early stages of the disease.
Neuroglee Therapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Neuroglee Therapeutics — Funding & Investors." VCBacked, September 9, 2021, https://www.vcbacked.co/company/neuroglee-therapeutics. Accessed September 29, 2026.
VCBacked. (2021). Neuroglee Therapeutics — Funding & Investors. Retrieved September 29, 2026, from https://www.vcbacked.co/company/neuroglee-therapeutics
{{cite web |title=Neuroglee Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/neuroglee-therapeutics |website=VCBacked |access-date=September 29, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated